

### Mortality Early And 3-5 Years After Endo Repair Of Juxtarenal And Complex AAAs In The US Aortic Research Consortium (ARC) Registry Is Less Than That Reported For Comparable Open Repairs




November 19<sup>th</sup>, 2024  
Veith Symposium, New York, NY

### Disclosures

- Cook Medical, Phillips Imaging, Cryolife
- Research grants
- Case proctor
- Consult

All compensation goes to UMass Memorial Foundation and none to me personally.

#### Editor's Choice – Comparison of Open Surgery and Endovascular Techniques for Juxtarenal and Complex Neck Aortic Aneurysms Study (UK COMPLEX)




mortality rate did not hold the assumption of proportional hazards owing to a reversal of treatment effect direction during the follow up period (Fig. 4). Specifically, there is a peri-operative survival benefit for endovascular techniques but a later disadvantage. This crossover of direction occurred at 10.3 months for EVAR vs. OSR and 12.1 months for FEVAR vs. OSR. Statistically, non-proportional hazards were confirmed with an assessment of Schoenfeld residuals against the rank of time giving a  $p$  value of  $< .001$ . Like to the late all cause mortality results, the overall survival benefit with OSR over endovascular techniques was not seen in the 0–4 mm neck length group. For these patients, overall survival between EVAR vs. OSR and FEVAR vs. OSR was equivalent at 3.5 years of follow up. Kaplan–Meier graphs showing comparative overall survival data for the six subgroups are shown in Figure 5. Comparative analysis results by subgroup are presented in Table 5 and the

Conclusion: FEVAR proves notably superior to EVAR in comparable midterm survival. For patients with short neck ( $\leq 4$  mm) and complex neck ( $\geq 10$  mm) AAAs, overall survival was worse in endovascularly treated patients compared with OSR despite relative peri-operative safety. This warrants further research and a re-appraisal of the current clinical application of endovascular strategies, particularly in patients with poor general survival outlook owing to comorbidity and age.

Eur J Endovasc Surg. 2024

#### Editor's Choice – Comparison of Open Surgery and Endovascular Techniques for Juxtarenal and Complex Neck Aortic Aneurysms: The UK COMPLEX Aneurysm Study (UK-COMPASS) – Peri-operative and Midterm Outcomes



n=366 FEVAR

n=621 OSR

2008


2024

### UNITED STATES AORTIC RESEARCH CONSORTIUM




### United States F/BEVAR Aortic Research Consortium (ARC)

- 10 US sites
- Prospective, physician-sponsored studies
- Independent monitoring, FDA audited
- Similar device design with selective use of fenestrations and branches



University of Washington (Matthew Swann)

University of California San Francisco (Warren Klapper)

University of Texas Houston (Guillermo Ochoa)

University of Texas South Western (Carlos W. Teodoro)

University of Alabama (Mark W. Beck)


Boca Raton Florida (Anthony Lee)

University of North Carolina (Mark A. Eckert)

University of Pennsylvania (Barrie B. Schaner)

Mass General Hospital (Mark Fogarty)

University of Massachusetts (Andreas Schanzer)



	Total n=3453	TAAA (1-5) n=2357	Complex AAA n=1096	p-value
Age at index procedure, mean (std)	73.5 (8.3)	72.8 (8.6)	75.1 (7.5)	<0.0001
Male sex	2423 (70)	1546 (66)	877 (80)	<0.0001
Race (can select more than one)				
White	2954 (86)	1962 (83)	992 (91)	<0.0001
Black	278 (8.1)	226 (9.6)	52 (4.7)	<0.0001
Asian	36 (1.0)	22 (0.9)	14 (1.3)	0.35
American Indian or Alaska Native	13 (0.4)	7 (0.3)	6 (0.6)	0.37
Native Hawaiian or Pacific Islander	2 (0.1)	2 (0.1)	0 (0)	0.99
Other/unknown	91 (2.6)	71 (3.0)	20 (1.8)	0.043
Hispanic ethnicity	77 (2.2)	63 (2.7)	14 (1.3)	0.010
Comorbidities				
CAD	1647 (48)	1062 (45)	585 (54)	<0.0001
COPD	1211 (35)	809 (34)	402 (37)	0.19
Renal failure requiring dialysis	61 (1.8)	53 (2.3)	8 (0.7)	0.002
Diabetes	523 (15)	334 (14)	189 (17)	0.019
Hypertension	3169 (92)	2176 (92)	993 (91)	0.06
Current tobacco use	933 (27)	624 (27)	309 (28)	0.3
Prior EVAR	531 (16)	304 (13)	227 (24)	<0.0001
Technical success	3327 (97)	2259 (96)	1068 (98)	0.030
ICU LOS days, mean (std)	3.3 (5.4)	3.8 (6.0)	2.0 (3.4)	<0.0001
Total LOS days, mean (std)	6.4 (9.4)	7.2 (9.3)	4.8 (9.4)	<0.0001

	Total n=3453	TAAA (1-5) n=2357	Complex AAA n=1096	p-value
Age at index procedure, mean (std)	73.5 (8.3)	72.8 (8.6)	75.1 (7.5)	<0.0001
Male sex	2423 (70)	1546 (66)	877 (80)	<0.0001
Race (can select more than one)				
White	2954 (86)	1962 (83)	992 (91)	<0.0001
Black	278 (8.1)	226 (9.6)	52 (4.7)	<0.0001
Asian	36 (1.0)	22 (0.9)	14 (1.3)	0.35
American Indian or Alaska Native	13 (0.4)	7 (0.3)	6 (0.6)	0.37
Native Hawaiian or Pacific Islander	2 (0.1)	2 (0.1)	0 (0)	0.99
Other/unknown	91 (2.6)	71 (3.0)	20 (1.8)	0.043
Hispanic ethnicity	77 (2.2)	63 (2.7)	14 (1.3)	0.010
Comorbidities				
CAD	1647 (48)	1062 (45)	585 (54)	<0.0001
COPD	1211 (35)	809 (34)	402 (37)	0.19
Renal failure requiring dialysis	61 (1.8)	53 (2.3)	8 (0.7)	0.002
Diabetes	523 (15)	334 (14)	189 (17)	0.019
Hypertension	3169 (92)	2176 (92)	993 (91)	0.06
Current tobacco use	933 (27)	624 (27)	309 (28)	0.3
Prior EVAR	531 (16)	304 (13)	227 (24)	<0.0001
Technical success	3327 (97)	2259 (96)	1068 (98)	0.030
ICU LOS days, mean (std)	3.3 (5.4)	3.8 (6.0)	2.0 (3.4)	<0.0001
Total LOS days, mean (std)	6.4 (9.4)	7.2 (9.3)	4.8 (9.4)	<0.0001

	Total n=3453	Complex AAA n=1096
Age at index procedure, mean (std)	73.5 (8.3)	75.1 (7.5)
Male sex	2423 (70)	877 (80)
Race (can select more than one)		
White	2954 (86)	992 (91)
Black	278 (8.1)	52 (4.7)
Asian	36 (1.0)	14 (1.3)
American Indian or Alaska Native	13 (0.4)	6 (0.6)
Native Hawaiian or Pacific Islander	2 (0.1)	0 (0)
Other/unknown	91 (2.6)	20 (1.8)
Hispanic ethnicity	77 (2.2)	14 (1.3)
Comorbidities		
CAD	1647 (48)	585 (54)
COPD	1211 (35)	402 (37)
Renal failure requiring dialysis	61 (1.8)	8 (0.7)
Diabetes	523 (15)	189 (17)
Hypertension	3169 (92)	993 (91)
Current tobacco use	933 (27)	309 (28)
Prior EVAR	531 (16)	227 (24)
Technical success	3327 (97)	1068 (98)
ICU LOS days, mean (std)	3.3 (5.4)	2.0 (3.4)
Total LOS days, mean (std)	6.4 (9.4)	4.8 (9.4)

	Total n=3453	Complex AAA n=1096
Age at index procedure, mean (std)	73.5 (8.3)	75.1 (7.5)
Male sex	2423 (70)	877 (80)
Race (can select more than one)		
White	2954 (86)	992 (91)
Black	278 (8.1)	52 (4.7)
Asian	36 (1.0)	14 (1.3)
American Indian or Alaska Native	13 (0.4)	6 (0.6)
Native Hawaiian or Pacific Islander	2 (0.1)	0 (0)
Other/unknown	91 (2.6)	20 (1.8)
Hispanic ethnicity	77 (2.2)	14 (1.3)
Comorbidities		
CAD	1647 (48)	585 (54)
COPD	1211 (35)	402 (37)
Renal failure requiring dialysis	61 (1.8)	8 (0.7)
Diabetes	523 (15)	189 (17)
Hypertension	3169 (92)	993 (91)
Current tobacco use	933 (27)	309 (28)
Prior EVAR	531 (16)	227 (24)
Technical success	3327 (97)	1068 (98)
ICU LOS days, mean (std)	3.3 (5.4)	2.0 (3.4)
Total LOS days, mean (std)	6.4 (9.4)	4.8 (9.4)




	Total n=3453	Complex AAA n=1096
Age at index procedure, mean (std)	73.5 (8.3)	75.1 (7.5)
Male sex	2423 (70)	877 (80)
Race (can select more than one)		
White	2954 (86)	992 (91)
Black	278 (8.1)	52 (4.7)
Asian	36 (1.0)	14 (1.3)
American Indian or Alaska Native	13 (0.4)	6 (0.6)
Native Hawaiian or Pacific Islander	2 (0.1)	0 (0)
Other/unknown	91 (2.6)	20 (1.8)
Hispanic ethnicity	77 (2.2)	14 (1.3)
Comorbidities		
CAD	1647 (48)	585 (54)
COPD	1211 (35)	402 (37)
Renal failure requiring dialysis	61 (1.8)	8 (0.7)
Diabetes	523 (15)	189 (17)
Hypertension	3169 (92)	993 (91)
Current tobacco use	933 (27)	309 (28)
Prior EVAR	531 (16)	227 (24)
Technical success	3327 (97)	1068 (98)
ICU LOS days, mean (std)	3.3 (5.4)	2.0 (3.4)
Total LOS days, mean (std)	6.4 (9.4)	4.8 (9.4)

	Total n=3453	Complex AAA n=1096
Age at index procedure, mean (std)	73.5 (8.3)	75.1 (7.5)
Male sex	2423 (70)	877 (80)
Race (can select more than one)		
White	2954 (86)	992 (91)
Black	278 (8.1)	52 (4.7)
Asian	36 (1.0)	14 (1.3)
American Indian or Alaska Native	13 (0.4)	6 (0.6)
Native Hawaiian or Pacific Islander	2 (0.1)	0 (0)
Other/unknown	91 (2.6)	20 (1.8)
Hispanic ethnicity	77 (2.2)	14 (1.3)
Comorbidities		
CAD	1647 (48)	585 (54)
COPD	1211 (35)	402 (37)
Renal failure requiring dialysis	61 (1.8)	8 (0.7)
Diabetes	523 (15)	189 (17)
Hypertension	3169 (92)	993 (91)
Current tobacco use	933 (27)	309 (28)
Prior EVAR	531 (16)	227 (24)
Technical success	3327 (97)	1068 (98)
ICU LOS days, mean (std)	3.3 (5.4)	2.0 (3.4)
Total LOS days, mean (std)	6.4 (9.4)	4.8 (9.4)

	Total n=3453	Complex AAA n=1096
Age at index procedure, mean (std)	73.5 (8.3)	75.1 (7.5)
Male sex	2423 (70)	877 (80)
Race (can select more than one)		
White	2954 (86)	992 (91)
Black	278 (8.1)	52 (4.7)
Asian	36 (1.0)	14 (1.3)
American Indian or Alaska Native	13 (0.4)	6 (0.6)
Native Hawaiian or Pacific Islander	2 (0.1)	0 (0)
Other/unknown	91 (2.6)	20 (1.8)
Hispanic ethnicity	77 (2.2)	14 (1.3)
Comorbidities		
CAD	1647 (48)	585 (54)
COPD	1211 (35)	402 (37)
Renal failure requiring dialysis	61 (1.8)	8 (0.7)
Diabetes	523 (15)	189 (17)
Hypertension	3169 (92)	993 (91)
Current tobacco use	933 (27)	309 (28)
Prior EVAR	531 (16)	227 (24)
Technical success	3327 (97)	1068 (98)
ICU LOS days, mean (std)	3.3 (5.4)	2.0 (3.4)
Total LOS days, mean (std)	6.4 (9.4)	4.8 (9.4)

30-day or in-hospital mortality (n=3481)

**30-Day Mortality (11/13/24): 101/3481 = 2.9%**



### 1,681 Patients / 6,349 Target Vessels

Mid-term Renal and Mesenteric Artery Outcomes During Fenestrated and Branched Endovascular Aortic Repair for Complex Abdominal and Thoracoabdominal Aortic Aneurysms in the United States Aortic Research Consortium

*Emanuel R. Tenorio MD, PhD\*, Andres Sanchez MD†, Carlos H. Timaran MD‡, Darren B. Schneider MD§, Bernardo C. Mendes MD||, Matthew J. Engleton MD¶, Mark A. Farber MD#, Federico Escquil Parodi MD#, Warren J. Gaitney MD\*\*, Adam W. Beck MD††, Matthew P. Sweet MD‡‡, Yong Huang MD, PhD†††, Gustavo S. Oderich MD†††† and on behalf of the U.S. Fenestrated and Branched Aortic Research Consortium§§*

Renal target artery stents <i>5-year Kaplan-Meier Estimates (%)</i>	Fenestration n = 2166	Branch n = 989	P value
Primary patency	94±1	83±3	<.001
Secondary patency	97±1	89±2	<.001
Freedom from target vessel instability	88±2	80±2	.001

Tenorio E et al. Ann Surg 2023

### Juxta/Para Sac Behavior (n = 1096)

Study Cohort n = 1096

**SVS Sac Behavior Definitions**

- Expansion: sac diameter increase ≥ 5 mm
- Regression: sac diameter decrease ≥ 5 mm
- Stable: change in diameter < 5 mm in either direction

Expansion n = 83 (8.6%)

Non-expansion n = 767 (91.4%)

Regression n = 427 (50%)

Stable n = 340 (44%)

### United States Aortic Research Consortium

- Thoughts
  - Largest dataset of F/BEVAR in the world
  - FDA audited
  - Outcomes superior to open repair

### Open Surgical Repair of Complex AAA in Large Single Center Studies

Author (Reference)	n	30-day Mortality	Renal failure	Dialysis
Giulini et al (Eur JVES 2000)	56	3.6%	-	2%
Ayri et al (Ann Vas Sur 2001)	53	11%	-	-
Sarac et al (J Vasc Surg 2002)	138	5.1%	22%	3%
Shortell et al (J Vasc Surg 2003)	112	6%	12%	3%
Bicknell et al (Eur JVES 2003)	44	6.8%	-	-
Kudo et al (J Vasc Surg 2008)	18	0	17%	5.6%
Chiesa et al (J Vasc Surg 2006)	119	7.6%	18%	5.8%
West et al (J Vasc Surg 2006)	243	2.5%	22%	2%
Knott et al (J Vasc Surg 2007)	126	0.8%	22%	1%
<b>Total</b>	<b>1202</b>	<b>4.2%</b>	<b>19%</b>	<b>3.8%</b>

### Open vs Fenestrated Repair for Complex AAA in the United States

Review of NSQIP Database on Juxtarenal Aneurysms

	Open Repair n = 598	Fenestrated Repair n = 629 patients
Mean age	73	71
30-day mortality	4.5%	2%
Dialysis	6%	2%
Return to OR	9%	-
Re-intervention	-	17%
Branch patency	-	93%

**2x+ mortality**  
**3x+ dialysis**

Linsen et al. J Vasc Surg 2012

### Systematic Review of Open vs Fenestrated Repair for Complex AAA

Systematic	Open Repair (n = 1164)	Fenestrated Endografts (n = 368)	RR (95% CI)	P value	
30-day mortality	3.6%	1.4%	0.4-3.1	1.03 (1.01-1.04)	.02
Renal impairment	20%	15%	11.5-18.7	1.01 (1.01-1.12)	.03
Dialysis	1.4%	1.4%	0.5-3.1	1.00 (0.99-1.01)	1
Primary endoleak	-	6%	3.1-7.8	-	-
Vessel patency	97%	95.4-97.8	-	-	-
Re-intervention	15%	11.5-18.7	0.87 (0.83-0.91)	.0001	

**2x+ mortality**  
**5x+ reinterventions**

Nordon et al. Eur J Vasc Surg 2009

### Outcomes of Open Surgical Repair and Fenestrated Repair of CAAAs in the SVS VQI

	Age <65				Age 65-75			
	FEVAR	OSR	OR (95% CI)	P value	FEVAR	OSR	OR (95% CI)	P value
30-day mortality	0.9%	2.1%	0.4(0.07-1.44)	.22	2.2%	5.0%	0.5(0.30-0.79)	.004
Dialysis	1.3%	2.6%	0.5(0.14-1.43)	.24	1.2%	5.4%	0.6(0.35-0.89)	<.001
Cardiac complications	0.4%	5.0%	0.15(0.03-0.47)	.005	2.5%	7.6%	0.42(0.28-0.62)	<.001
Pulmonary complications				.002	2.5%	12%	0.29(0.28-0.62)	<.001
Any complication				.001	8%	23%	0.38(0.26-0.42)	<.001

**For age > 65**  
**2x+ mortality**  
**3x+ dialysis, cardiac, pulmonary complications**

Rastogi et al. Eur J Vasc Endovasc Surg 2023

### Long-Term Propensity-Matched Comparison of Fenestrated Endovascular Aneurysm Repair and Open Surgical Repair of Complex Abdominal Aortic Aneurysms

**Abstract**  
 Purpose: This study investigated the long-term outcomes of patients treated with fenestrated and branched endovascular aneurysm repair (F/BEVAR) or open surgical repair (OSR) for complex abdominal aortic aneurysms (CAAA). Complex abdominal aortic aneurysms are defined as aneurysms that involve the renal or mesenteric arteries and extend up to the level of the celiac axis or diaphragmatic hiatus but do not extend past the thoracic aorta. This study compares with a propensity score matching the outcomes of these procedures from 3 high-volume aortic centers. **Patients and Methods:** All patients with CAAA undergoing repair at 2 centers between January 2010 and June 2016 were included. The long-term imaging follow-up consisted of a yearly computed tomography angiography (CTA) in the F/BEVAR group. Yearly abdominal ultrasonography and yearly CTA were performed in the OSR group. The primary endpoint was long-term mortality, aneurysm-related mortality, and chronic renal decline (CRD). **Results:** A total of 100 patients were included in the propensity score matching analysis. The overall follow-up was 27 months. There was no significant difference in long-term overall mortality (95% CI in 0.35-0.39) between F/BEVAR (n = 50) and OSR (n = 50). In the F/BEVAR and OSR groups, respectively, during follow-up, late renal function decline occurred in 27 (27%) versus 40 patients (40%) in the F/BEVAR group and 5 (10%) in the OSR group (p = 0.03). **Conclusions:** The differences in overall and aneurysm-related mortality were observed. Chronic renal decline was significantly higher after OSR, which represents the major long-term risk of F/BEVAR. These data support results that the outcomes of CAAA repair performed by a single experienced operator in 3 high-volume centers, and followed with a strict surveillance imaging follow-up.

Tinelli et al. Eur J Vasc Endovasc Surg 2024

### Open vs Fenestrated Repair for Complex AAA in France

Review of 2 High Volume Centers on CAAA

	Open Repair n = 102	Fenestrated Repair n = 102 patients	p-value
Long-term overall mortality	36.3%	40.2%	0.40
Aneurysm-related mortality	5.8%	6.8%	0.30
Late renal function decline	47.4%	27.8%	<0.01
Reinterventions	5.1%	23.5%	<0.01


**2x+ renal function decline**  
**4x+ Reinterventions**

Tinelli et al. Eur J Vasc Endovasc Surg 2024

### 2019 ESVES AAA guidelines

Recommendation	Class	Level
95 In patients with CAAs, <b>open repair or complex endovascular repair should be considered</b> based on patient status, anatomy, local expertise, team experience and patient preference	IIa	C
96 In complex endovascular AAA repair, <b>FB-EVAR</b> should be considered the <b>preferred option</b> when feasible	IIa	C
97 In complex endovascular AAA repair, parallel grafts, endo-stables, in situ fenestrations may be considered in the <b>emergency setting</b> when fenestrated grafts are not indicated or available or as a bail out, ideally restricted to <b>s2 parallel grafts</b>	IIa	C
98 In patients with CAAs, <b>new techniques or concepts</b> (EVAS, in situ, etc) are <b>not recommended as first line of treatment</b>	III	C
99 In patients with <b>ruptured CAAs</b> , <b>open repair or complex endovascular repair</b> (with PMEGs, off the shelf or parallel grafts) may be considered based on patient status, anatomy, local experience, team experience and patient preference	IIa	C

Warshawski A, et al. Eur J Vasc Endovasc Surg 2019



### Conclusions

- F/BEVAR is associated with lower morbidity and mortality compared to open surgical repair for complex AAA, despite being used in older and higher risk patients
- Limitations of F/BEVAR are important to acknowledge: secondary intervention, limited access, regulatory hurdles, cost, and need for surveillance
- While open and endovascular repair are valuable, it's time to stop starting and ending every talk with, "Open repair is the gold standard." Because it no longer is.
- The US ARC has established a higher level of evidence supporting use of FB-EVAR in most patients with CAAA (and TAAAs)

